Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
16.32 | 7.59 | 7.67 | 7.80 | |
Current Ratio |
16.66 | 7.82 | 7.89 | 8.13 | |
Net Debt/EBITDA |
7.08 | 5.42 | 5.28 | 6.18 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.63 | 1.02 | 1.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.51) | (0.35) | (0.59) | (0.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.51) | (0.35) | (0.59) | (0.46) | |
Cash per Share |
4.17 | 3.70 | 3.23 | 2.74 | |
Shareholders Equity per Share |
3.99 | 3.38 | 2.95 | 2.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.99 | 3.38 | 2.95 | 2.55 | |
Free Cash Flow |
(40.37) | (28.22) | (46.39) | (37.08) | |
Working Capital |
315.96 | 271.21 | 229.83 | 200.54 | |
Net Current Asset Value |
308.96 | 271.21 | 229.83 | 200.54 | |
| Other line items | |||||
Average Payables |
4.65 | 8.70 | 8.42 | 9.45 | |
Average Assets |
416.96 | 389.94 | 353.52 | 311.94 | |
Average Common Equity |
387.15 | 357.15 | 322.40 | 284.29 |
Columns are period end dates